October 8, 2015 2:53 PM | 1 min read
MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO
As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented results from a Phase 1 single ascending dose trial of CTP-656, a next generation potentiator being developed for the treatment of cystic fibrosis. In the Phase 1 healthy volunteer trial comparing CTP-656 to current standard of care Kalydeco®, CTP-656 provided a superior pharmacokinetic profile that supports once-daily dosing. CTP-656 is a new chemical entity designed by Concert to provide superior pharmacokinetic properties while leveraging the known safety and efficacy of Kalydeco. The results were presented during a poster session at the North American Cystic Fibrosis Conference in Phoenix, AZ. "With CTP-656 we aim to develop another treatment option to meaningfully enhance patient care. In this Phase 1 trial,
See full press release
MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO
As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.